Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies

Trial Profile

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms ZOSTER-039
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017.
    • 18 May 2017 The trial has been completed in Sweden (end date: 6 Jan 2017).
    • 21 Apr 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top